mTOR Signaling and Cancer Progression

mTOR is a serine/threonine protein kinase that acts as a master regulator of cellular metabolism and growth. It controls protein synthesis, nutrient sensing, and cell proliferation by integrating signals from growth factors, amino acids, and energy status. Dysregulation of mTOR signaling is implicated in cancer development and progression.

Aberrant mTOR activation drives cancer progression by enhancing protein synthesis, increasing cell growth, and promoting cell survival. Hyperactive mTOR signaling allows cancer cells to bypass normal growth checkpoints and accumulate additional mutations. This sustained proliferation supports tumorigenesis and enables malignant transformation.

mTOR activity is regulated by multiple upstream pathways including growth factor signaling through PI3K/AKT, nutrient availability sensors, and energy status via AMPK. These signals converge on mTOR complexes to modulate protein synthesis, autophagy, and metabolic processes. Disruption of these regulatory mechanisms contributes to oncogenic mTOR activation.

mTOR inhibitors can suppress uncontrolled cell growth and protein synthesis in cancer cells, making mTOR an attractive therapeutic target. Blocking mTOR signaling pathways reduces tumor cell proliferation and can restore apoptosis. Several mTOR-targeting drugs are used clinically to treat various cancer types.

mTOR regulates cellular metabolism by controlling protein synthesis, lipid production, and nucleotide synthesis—processes essential for rapid cancer cell division. Hyperactive mTOR signaling reprograms metabolism to support increased anabolic demands. This metabolic rewiring enables cancer cells to sustain aggressive growth and survival.

mTOR exists in two distinct complexes: mTORC1, which primarily regulates protein synthesis and cell growth, and mTORC2, which controls cell survival and metabolism. mTORC1 is sensitive to nutrient availability and growth factors, while mTORC2 responds to growth signals. Both complexes contribute to oncogenic signaling in cancer cells.

Inhibiting mTOR signaling reduces protein synthesis, slows cell proliferation, and can trigger apoptosis in cancer cells. mTOR inhibition also restores autophagy, allowing cells to degrade damaged components. This multi-faceted suppression of cancer cell growth makes mTOR inhibitors valuable in cancer treatment strategies.